硫酸阿托品微量眼用溶液(ARVN002)延缓儿童近视进展的有效性和安全性的随机、双盲、安慰剂对照、多中心III期临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase III clinical study of the efficacy and safety of atropine sulfate micro-ophthalmic solution (ARVN002) in delaying myopia progression in children
主要目的:评估每日微量给予0.01%和0.1%ARVN002延缓6~12岁儿童近视进展的有效性。次要目的:评估每日微量给予0.01%和0.1%ARVN002在6~12岁儿童中的安全性。
[Translation] Main objective: To evaluate the effectiveness of daily micro-administration of 0.01% and 0.1% ARVN002 in delaying the progression of myopia in children aged 6-12 years. Secondary objective: To evaluate the safety of daily micro-dose 0.01% and 0.1% ARVN002 in children 6-12 years old.
老视患者使用微量给药器给予ARVN003以暂时性改善近视力的有效性和安全性的随机、多中心、双盲、安慰剂对照、III期临床研究
[Translation] A randomized, multicenter, double-blind, placebo-controlled, phase III clinical study of the efficacy and safety of ARVN003 administered using a microdrug dispenser to temporarily improve near vision in presbyopic patients
在成人老视患者中评估使用微量给药器给予盐酸毛果芸香碱微量眼用溶液暂时性改善近视力的有效性和安全性。
[Translation] To evaluate the efficacy and safety of pilocarpine hydrochloride micro-ophthalmic solution administered using a microdose device to temporarily improve near vision in adult patients with presbyopia.
一项评估曲安奈德脉络膜上腔注射混悬液(ARVN001) 在糖尿病性黄斑水肿患者中的安全耐受性、 药代动力学特征及初步疗效的多中心、 开放、单臂的 I 期临床研究
[Translation] A multicenter, open-label, single-arm phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of triamcinolone acetonide suprachoroidal injection suspension (ARVN001) in patients with diabetic macular edema
评价ARVN001脉络膜上腔注射液在糖尿病性黄斑水肿受试者中的安全耐受性、药代动力学特征和有效性
[Translation] To evaluate the safety tolerability, pharmacokinetics and efficacy of ARVN001 suprachoroidal injection in subjects with diabetic macular edema
100 Clinical Results associated with Changzhou Jimu Biotechnology Co., Ltd.
0 Patents (Medical) associated with Changzhou Jimu Biotechnology Co., Ltd.
100 Deals associated with Changzhou Jimu Biotechnology Co., Ltd.
100 Translational Medicine associated with Changzhou Jimu Biotechnology Co., Ltd.